Logo image of SYN

SYNTHETIC BIOLOGICS INC (SYN) Stock Fundamental Analysis

NYSEARCA:SYN - NYSE Arca - US87164U4094 - Common Stock - Currency: USD

1.02  +0.01 (+0.99%)

After market: 1.1 +0.08 (+7.84%)

Fundamental Rating

1

Overall SYN gets a fundamental rating of 1 out of 10. We evaluated SYN against 571 industry peers in the Biotechnology industry. SYN may be in some trouble as it scores bad on both profitability and health. SYN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SYN has reported negative net income.
SYN Yearly Net Income VS EBIT VS OCF VS FCFSYN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -21.59%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SYN Yearly ROA, ROE, ROICSYN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SYN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYN Yearly Profit, Operating, Gross MarginsSYN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for SYN has been increased compared to 1 year ago.
There is no outstanding debt for SYN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SYN Yearly Shares OutstandingSYN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
SYN Yearly Total Debt VS Total AssetsSYN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -4.41, we must say that SYN is in the distress zone and has some risk of bankruptcy.
SYN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.41
ROIC/WACCN/A
WACCN/A
SYN Yearly LT Debt VS Equity VS FCFSYN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 4.14 indicates that SYN has no problem at all paying its short term obligations.
A Quick Ratio of 4.14 indicates that SYN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.14
Quick Ratio 4.14
SYN Yearly Current Assets VS Current LiabilitesSYN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.86% over the past year.
EPS 1Y (TTM)71.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 7.32% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.44%
EPS Next 2Y14.45%
EPS Next 3Y14.34%
EPS Next 5Y7.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SYN Yearly Revenue VS EstimatesSYN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
SYN Yearly EPS VS EstimatesSYN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SYN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SYN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYN Price Earnings VS Forward Price EarningsSYN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.05
SYN Per share dataSYN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as SYN's earnings are expected to grow with 14.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.45%
EPS Next 3Y14.34%

More info and screens

0

5. Dividend

5.1 Amount

SYN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNTHETIC BIOLOGICS INC

NYSEARCA:SYN (10/12/2022, 8:04:00 PM)

After market: 1.1 +0.08 (+7.84%)

1.02

+0.01 (+0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2022-08-11/bmo
Earnings (Next)11-02 2022-11-02/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners10.93%
Ins Owner Change0%
Market Cap16.16M
Analysts80
Price Target6.12 (500%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB N/A
EV/EBITDA 2.05
EPS(TTM)-1.21
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS3.89
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.14
Quick Ratio 4.14
Altman-Z -4.41
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55%
EPS Next Y38.44%
EPS Next 2Y14.45%
EPS Next 3Y14.34%
EPS Next 5Y7.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A